Reducing the Usage of Oral Corticosteroids in the Management of Asthma
TeleECHO Series
Post-Test/Evaluation
Questions marked with a
*
are required
23%
Contact Information
First Name
Last Name
Email Address
Credentials/Degree (MD, DO, RN, etc.)
Date of Participation
Month
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Day
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Year
2018
2019
2020
2021
2022
2023
2024
2025
Oral corticosteroids (OCS):
A. Are frequently prescribed in patients with severe asthma
B. Are prescribed for patients with severe asthma as low dose (<5mg/day) prednisone and are free from developing any OCS-related complications
C. In short bursts, are not associated with any related complications in individuals with asthma
D. A and B
E. B and C
Referrals to asthma specialists:
A. Are found to delay care that can result in poor patient outcomes
B. Are recommended in those patients with anaphylaxis or food allergy
C. Are recommended for the patient who has been on maintenance OCS for over 12 months
D. A and C
E. B and C
Cindy is a 12-year-old girl with a history of asthma who presented to the emergency room with a 3-day history of increased difficulty breathing. She was also coughing and wheezing. This is her second exacerbation this year requiring emergent care. She has been maintained with high-dose ICS/LABA. Oral corticosteroids had been prescribed with her non-emergent exacerbations. In the emergency department, her oxygen saturation was 85% and her respiratory rate was 40 breaths/min. She had significant difficulty breathing and poor air entry bilaterally to both lung bases, with wheezing in the upper lung zones. She was treated with salbutamol/ipratropium and received intravenous steroids. Her chest x-ray showed hyperinflation and no focal findings.
Laboratory results:
-FEV1 <50% predicted
-Blood EOS 190/µL
How would you change her asthma treatment?
A. Add a LAMA to her inhaler regimen
B. Add a biologic
C. Continue oral prednisone upon discharge
D. Any of the above
Brian is a 20-year-old man with a 2-year history of eosinophilic asthma currently on high-dose ICS/LABA with a LAMA added 2 months ago. His use of his rescue inhaler has increased over the last month. He is home from college for Holiday break with a new complaint of facial pain/pressure, purulent nasal discharge, and nasal obstruction. He is referred to a local ENT who reported decreased sense of smell and confirmed the presence of nasal polyps through endoscopy. Which of the following are preferred treatment options for Brian?
A. Add prednisone 15 mg daily to current regimen
B. Transition treatment to dupilumab
C. Transition treatment to benralizumab
D. Transition treatment to mepolizumab
E. B and D
F. Any of the above
Start
Powered by
QuestionPro
Loading...
close
drag_indicator
close
Yes
Cancel
Continue
Answer Question
Continue Without Answering
Keep Data
Discard
close
drag_indicator
highlight_off